Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Stroke

    Current Location

    Search
    Stroke
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    188 Clinical Trials near Fairhope, AL

    54 Weight Loss Trials near Miami, FL

    177 Clinical Trials near Alexandria, LA

    204 Clinical Trials near Hazelwood, MO

    161 Clinical Trials near Bridgeton, MO

    13 Weight Loss Trials near Dallas, TX

    175 Clinical Trials near Edinburg, TX

    46 Alzheimer's Disease Trials near Dallas, TX

    Top Schwannomatosis Clinical Trials

    Top Bronchiolitis Clinical Trials

    Top Medulloblastoma Clinical Trials

    Top Cataract Clinical Trials

    By Trial

    Cranial Nerve Neuromodulation for Stroke

    Brain Stimulation for Stroke

    Supported Reaching + Abduction Loading for Stroke

    Ischemic Conditioning for Stroke Recovery

    Cognitive Strategies for Stroke

    Vibrotactile Stimulation for Stroke Recovery

    Direct Current Stimulation for Stroke

    BreEStim for Stroke

    ARFI Ultrasound for Stroke Risk Assessment in Carotid Artery Plaque

    MyStroke for Stroke Survivors

    Balance Training for Stroke

    Ketamine for Stroke

    Related Searches

    Top Prostate-cancer Clinical Trials near Los Angeles, CA

    Top Peanut-allergy Clinical Trials

    CHEC Intervention for Caregiver Support

    Top Depression Clinical Trials near Detroit, MI

    Millipede System for Ischemic Stroke

    Nintedanib for Interstitial Lung Disease

    FibroScan for Heart Failure

    Retro-TCE Capsule for Lower GI Tract Imaging

    K-757 + K-833 for Obesity

    Exercise Incentives + Corticosteroid Injections for Osteoarthritis

    Pulse Field Ablation for Ventricular Tachycardia

    Ultrasound Imaging for Pancreatic Cancer

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      81 Stroke Trials Near You

      Power is an online platform that helps thousands of Stroke patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Recombinant Factor VIIa for Hemorrhagic Stroke

      Columbus, Ohio
      The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Coma, Disability, Thrombosis, Pregnancy, Others
      Must Not Be Taking:Anticoagulants, Pro-coagulants, Heparin, Others

      350 Participants Needed

      Thrombectomy + Angioplasty/Stenting for Stroke

      Columbus, Ohio
      This trial tests if using a stent to open a blocked neck artery along with removing a brain clot is better than just removing the clot alone for stroke patients with severe artery blockages.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Refractory Hypertension, Intracranial Tumors, Others
      Must Not Be Taking:Anticoagulants

      404 Participants Needed

      Anticoagulation + Antiplatelet Therapy for Post-Operative Atrial Fibrillation

      Columbus, Ohio
      The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Permanent AF, Cardiogenic Shock, Liver Cirrhosis, Others
      Must Not Be Taking:Dual Antiplatelets

      3200 Participants Needed

      rFVIIa for Hemorrhagic Stroke

      Columbus, Ohio
      The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Coma, Disability, Thrombosis, Others
      Must Not Be Taking:Anticoagulants, Pro-coagulants, Heparin, Others

      860 Participants Needed

      Sovateltide for Stroke

      Columbus, Ohio
      Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Comatose, Intracranial Hemorrhage, Pregnancy, Others

      514 Participants Needed

      Cholesterol-Lowering Medication for Heart Attack

      Columbus, Ohio
      The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Sepsis, Atrial Fibrillation, Others

      6019 Participants Needed

      TS23 for Stroke

      Columbus, Ohio
      SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Recent Stroke, Hypertension, Others
      Must Not Be Taking:Thrombolytics, Anticoagulants, Antiplatelets, Others

      300 Participants Needed

      Scp776 for Stroke

      Columbus, Ohio
      A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Intracerebral Hemorrhage, Poor Circulation, End Stage Kidney, Others
      Must Not Be Taking:Anticoagulants

      120 Participants Needed

      BB-031 for Stroke

      Columbus, Ohio
      The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Large Stroke, Hemorrhage, Coagulopathy, Others
      Must Not Be Taking:Thrombolytics, Glycoprotein IIb/IIIa Inhibitors

      156 Participants Needed

      Redasemtide for Stroke

      Columbus, Ohio
      This trial is testing a medication called redasemtide to see if it can help adults who have had a stroke. The goal is to find out if this medication can protect brain cells and help them heal better after the stroke. Researchers are looking at both how well it works and if it is safe to use.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Consciousness Decrease, Recent Stroke, Others

      849 Participants Needed

      Left Atrial Appendage Exclusion for Stroke Prevention

      Columbus, Ohio
      This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Atrial Fibrillation, Heart Transplant, Infection, Others

      6573 Participants Needed

      Thrombectomy for Stroke

      Columbus, Ohio
      This trial tests whether removing blood clots from medium-sized brain vessels helps stroke patients. The procedure uses a special device to pull out the clot and restore blood flow. It targets patients with sudden strokes caused by clots in medium-sized vessels.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Intracranial Hemorrhage, Nursing Home, Major Co-morbid Illness, Pregnancy, Others

      530 Participants Needed

      PFO Closure Devices for Stroke Prevention

      Columbus, Ohio
      The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Atrial Fibrillation, Hypertension, Diabetes, Others
      Must Not Be Taking:Aspirin, Clopidogrel

      450 Participants Needed

      WATCHMAN FLX Device for Atrial Fibrillation

      Columbus, Ohio
      The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Active Bleed, Recent Stroke, Others
      Must Be Taking:Non-vitamin K Anticoagulants

      3000 Participants Needed

      IVUS-Guided PCI for Atherosclerosis

      Columbus, Ohio
      Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI. This is accomplished by improving the angiographic result with lesion and vessel assessment to guide stent selection and implantation and intravascular imaging following stent implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive literature supporting the use of IVUS in PCI, utilization remains low in the United States. An increasing number of high-risk or complex lesions are being treated with PCI and we hypothesize that the impact of IVUS in these complex lesions will be of increased importance in reducing clinical adverse events while remaining cost effective.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:STEMI, Cardiogenic Shock, Others

      3100 Participants Needed

      CPAP for Sleep Apnea After Stroke

      Columbus, Ohio
      The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Mechanical Ventilation, Pneumothorax, Others

      3062 Participants Needed

      Endovascular Thrombectomy for Stroke

      Columbus, Ohio
      STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Septic Embolus, Seizure, Pregnancy, Others

      1600 Participants Needed

      AMPLATZER PFO Occluder for Patent Foramen Ovale

      Columbus, Ohio
      The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Atherosclerosis, Intracardiac Thrombus, Pregnancy, Organ Failure, Others
      Must Not Be Taking:Antiplatelets

      1214 Participants Needed

      WATCHMAN Device for Stroke Prevention in Atrial Fibrillation

      Columbus, Ohio
      The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Stroke, Heart Failure, Mechanical Valve, Others
      Must Be Taking:Aspirin, Clopidogrel

      481 Participants Needed

      Motor Rehabilitation for Stroke

      Columbus, Ohio
      Constraint-induced movement therapy (CI therapy) is a highly efficacious treatment for residual motor disability in chronic stroke. Its effectiveness is believed to be due, at least in part, to the therapy's ability to aid the brain in "rewiring itself." For example, CI therapy produces increases in the amount of grey matter (the parts of the brain where neuron cell bodies are most closely clustered) in certain areas of the human brain (Gauthier et al., 2008). The cellular and molecular mechanisms that are responsible for this increase in grey matter volume are not known, however. Thus, it is unclear how the therapy helps brains "rewire" themselves. This study aims to better understand the timecourse and cellular/molecular nature of brain changes during CI therapy. Because there is currently no way to directly measure cellular/molecular changes in the brain noninvasively, this study will infer what is happening on a microstructural level using new MRI techniques (three dimensional pictures of the brain). For example, by charting the timecourse of grey matter changes during CI therapy, and cross-comparing this to what is known about the timecourses of different cellular/molecular processes, the investigators can gain a greater understanding of what cellular processes may be responsible for increases in grey matter. The investigators will gain additional information about which cellular processes are important for rehabilitation-induced improvement by measuring larger-scale changes (e.g., amount of blood flow through different brain areas) that accompany cellular changes. The investigators are hopeful that by better understanding how CI therapy can change the brain, the effectiveness of rehabilitation can be improved upon. For example, insight into the mechanisms of rehabilitation-induced brain change may suggest particular drug targets to increase brain plasticity. This study will help us better understand how the brain repairs itself after injury.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Dementia, Severe Pain, Kidney Disease, Others
      Must Not Be Taking:Botulinum Toxin

      31 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Stroke Trial

      Blood Clot Treatments for Stroke

      Columbus, Ohio
      The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with standard of care thrombolysis (0.9mg/kg IV rt-PA or 0.25mg/kg IV tenecteplase or TNK) within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      514 Participants Needed

      Asundexian for Stroke Prevention

      Columbus, Ohio
      This trial is testing asundexian, a new medicine that prevents blood clots, in people who had a non-heart-related stroke or high-risk mini-stroke. The goal is to see if it works better at reducing future strokes without increasing bleeding risks. Asundexian is developed by Bayer AG and might prevent thrombosis without increasing bleeding.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Atrial Fibrillation, Mechanical Valve, Others
      Must Be Taking:Antiplatelets

      12327 Participants Needed

      Intensive Infant Rehabilitation for Perinatal Stroke

      Columbus, Ohio
      This trial is testing a new therapy program called I-ACQUIRE for infants who have had a stroke. The program involves intensive sessions with therapists to help improve movement and strength. The study will compare two different amounts of therapy to usual treatments to see which works best.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:8 - 36

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Seizures, Fragile Health, Others
      Must Not Be Taking:Botulinum Toxin

      216 Participants Needed

      Milvexian for Stroke

      Columbus, Ohio
      This trial is testing whether milvexian can help prevent another stroke in people who have already had one by stopping blood clots from forming. Milvexian may reduce the risk of stroke without significant bleeding.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Intracranial Hemorrhage, Cardio-embolic Stroke, Bleeding Risk, Active Liver Disease, Others
      Must Be Taking:Antiplatelets

      15000 Participants Needed

      Anti-Coagulant + Anti-Platelet Therapy for Stroke Prevention

      Columbus, Ohio
      The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Intracranial Tumor, Cardiac Embolism, Others
      Must Not Be Taking:Thrombolytics, Antithrombotics, CYP3A4 Inhibitors

      1683 Participants Needed

      Apixaban vs Aspirin for Stroke Prevention in Atrial Fibrillation After Brain Bleed

      Columbus, Ohio
      Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Endocarditis, Hepatitis, Anemia, Others
      Must Not Be Taking:Anticoagulants, Antiplatelets

      700 Participants Needed

      WATCHMAN FLX Pro Device for Atrial Fibrillation

      Columbus, Ohio
      The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Liver Disease, Hypercoagulability, Stroke, Others
      Must Not Be Taking:Anticoagulants, P2Y12 Inhibitors

      1857 Participants Needed

      I-STROM Implementation for Stroke Rehabilitation

      Columbus, Ohio
      The primary objective of this study is to tailor and test implementation strategies to support the adoption of two upper extremity motor outcome measures for stroke: the Fugl-Meyer Assessment and the Action Research Arm Test. The study's interdisciplinary team will address this objective through the following specific aims: (a) Tailor a package of implementation strategies (referred to as I-STROM-Implementation STRategies for Outcome Measurement) to promote outcome measure use across the care continuum, (b) Determine the effectiveness of I-STROM on outcome measure adoption and (c) Evaluate the appropriateness, acceptability, and feasibility of I-STROM in rehabilitation settings across the country. The mixed-methods study design is informed by implementation science methodologies, and the tailoring of I-STROM will be guided by input from stakeholders, including occupational therapy practitioners and administrators. The investigators will collect robust quantitative and qualitative data by means of retrospective chart reviews, electronic surveys, and stakeholder focus groups. This study, "Strategies to Promote the Implementation of Outcome Measures in Stroke Rehabilitation," will address core barriers to outcome measure use through a package of implementation strategies, thus laying the groundwork for I-STROM scale-up in health systems nationwide.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-therapists, Non-Ohio License, Others

      484 Participants Needed

      Left Atrial Appendage Closure Devices for Atrial Fibrillation

      Columbus, Ohio
      The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial fibrillation (NVAF) to reduce the risk of stroke (blocked blood vessel or bleeding in brain) and systemic embolism (blockage in a blood vessel harming vital organs).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Stage IV Kidney Disease, Others
      Must Be Taking:Oral Anticoagulants

      1900 Participants Needed

      CLAAS Device for Atrial Fibrillation

      Columbus, Ohio
      This trial is testing a new heart device called the CLAAS® to see if it works as well as other similar devices. It is aimed at patients with a specific type of irregular heartbeat that can lead to strokes. The device helps by blocking off a small part of the heart to stop blood clots from forming.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Infection, Stroke, Heart Failure, Others
      Must Not Be Taking:Antiplatelets, Anticoagulants

      1600 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Stroke clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Stroke clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Stroke trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Stroke is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Stroke medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Stroke clinical trials?

      Most recently, we added Angioplasty for Stroke Risk Reduction, Computerized Decision Support for Stroke Prevention in Atrial Fibrillation and Adaptive Rowing Seating for Spinal Cord Injury to the Power online platform.

      Is it possible to 100% recover from a stroke?

      A completely symptom-free recovery does happen, but it’s uncommon—about 1 in 10 stroke survivors have no noticeable deficits by 3–6 months, while many more regain independence yet live with minor limitations. Your odds rise if the stroke is small, treated within hours (clot-busting drugs or thrombectomy), and followed by early, high-intensity rehab; age, other illnesses, and strong family support also matter. Even when full recovery isn’t reached, the brain can keep rewiring for months or years, so aggressive therapy and strict control of blood pressure, cholesterol, and lifestyle risks remain worthwhile.

      What triggers a stroke?

      A stroke is triggered the instant blood can’t reach part of the brain—either because a clot suddenly blocks an artery or a weakened vessel bursts. Long-standing problems such as high blood pressure, atrial fibrillation, diabetes, smoking, and cholesterol build-up make the vessels fragile, while short-term sparks like a surge in blood pressure (heavy exertion, intense stress, cocaine or binge drinking), a bad infection, severe dehydration, or head/neck injury can tip things over the edge. Controlling the chronic risks and avoiding those sudden spikes are the surest ways to lower your odds.

      What is the new procedure for stroke victims?

      Two main “new” procedures are worth knowing about. If a stroke is caught within the first day, doctors can now thread a tiny device into the brain’s artery (mechanical thrombectomy) to pull out large clots—even up to 24 hours after symptoms start. For people who are six months or more past an ischemic stroke and still have arm weakness, a recently approved treatment called paired vagus-nerve stimulation implants a pacemaker-like device in the chest; brief pulses are delivered during therapy sessions and, in a large study, nearly doubled the number of patients who regained meaningful arm use compared with therapy alone. Ask your stroke or rehab specialist which option, if any, fits your stage of recovery and medical history.

      What is the average age at the time of ischemic stroke?

      Across contemporary U.S. and European studies, the average (mean) age at first ischemic stroke is about 70–72 years overall—roughly 71 years in men and 74–75 years in women. Most strokes still occur after 65, but nearly 15–20 % now happen before age 55, so personal risk depends more on controllable factors such as blood-pressure, diabetes, smoking, and atrial fibrillation than on age alone.

      What are good signs after a brain stroke?

      Good signs after a stroke are the things doctors see when the brain is healing: 1) steadily improving neurological function—e.g., a weak arm or leg starts to move, speech becomes clearer, swallowing is safe, thinking is sharper; 2) growing independence—being able to sit, stand, walk, dress, or bathe with less help each week; and 3) no new problems—vital signs remain stable, follow-up scans show no bleeding or new damage, and there are no new bouts of confusion or weakness. If progress keeps inching forward over the first days to months, that generally predicts a better long-term recovery, while sudden setbacks should prompt a call to the medical team.

      Which side of the brain is worse to have a stroke?

      Neither hemisphere is automatically “worse.” What harms you most is how big the stroke is, which critical areas it hits (for example, language centers on the left or spatial-awareness areas on the right), and how fast doctors can restore blood flow. Large right-side strokes carry a slightly higher risk of early swelling and heart-rhythm problems, while left-side strokes more often steal speech, but in the long run size, exact location, and treatment speed—not simple left vs. right—determine survival and disability.

      How to stop a stroke in progress?

      A stroke in progress can only be halted by hospital teams, so the single lifesaving move is to get the patient to a stroke-ready ER fast. Spot symptoms with the BE-FAST check (Balance, Eyes, Face, Arm, Speech, Time), call 911, note when symptoms started, keep the person upright and nil-by-mouth, and let EMS transport. Every minute saved lets doctors give clot-busting medicine (within ~4½ h) or remove a clot mechanically (up to 24 h in select cases), drastically reducing brain damage and disability.

      What is the critical time after a stroke?

      “Time is brain.” Call 911 the moment you notice stroke signs, because the sooner doctors see you, the more treatment choices you have: clot-busting medication helps most if started within 4½ hours, and a catheter procedure to pull out a large clot can work in carefully selected cases up to 24 hours—but outcomes get worse with every minute’s delay. Getting to the hospital fast also lets the team quickly scan your brain, control bleeding or swelling, and begin early rehab, all of which greatly improve the chance of recovery.

      What heals the brain after a stroke?

      First, rapid hospital treatment (clot-busting drugs or a catheter procedure, plus careful control of blood pressure, sugar and swelling) “saves” threatened brain tissue—so minutes matter. In the weeks and months that follow, the surviving brain rewires itself and grows new blood vessels, and that self-repair works best when you give it the right signals: daily, task-specific rehab exercises, regular aerobic activity, good sleep, and strict control of smoking, blood pressure, cholesterol and diabetes; tools like non-invasive brain stimulation or certain medications are optional add-ons guided by specialists. Put simply, the brain heals through a mix of early damage-limiting care and long-term, repetitive practice in a healthy body, with emerging technologies offering extra (but still experimental) help for some people.

      What is the average stay in rehab after a stroke?

      For patients able to tolerate intensive therapy, the average stay in a U.S. inpatient rehabilitation hospital is about 15–18 days (roughly 2–3 weeks); if a skilled-nursing rehab unit is needed, expect closer to 4–5 weeks before stepping down to outpatient or home therapy several times a week. How long you personally stay hinges on stroke severity, other medical problems, progress on daily-living skills, insurance rules, and the safety of your home setup—so ask the rehab team what specific goals you must meet to move to the next level of care.